Stock listing

KRX:007390 NATURECELL Co., Ltd. (네이처셀) 주가

Follow NATURECELL Co., Ltd. into a list and get an email when it puts out news.

Share price · KRX:007390

₩20,250 KRW -1,200 (-5.6%)

Close on Nov 20, 2026

Past year -24.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
₩20,000 – ₩21,050 KRWNov 20, 2026
Volume
228,450 sharesNov 20, 2026
Market cap
₩1.07T KRWAt the close on Nov 20, 2026 · price × 53.08M shares outstanding
52-week range
₩16,550 – ₩36,950 KRWLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
₩5.43B KRWMedian day 206,849 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
NATURECELL Co., Ltd. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · KRX:007390 · KRW, adjusted for splits

DayCloseChange%OpenHighLowVolume
₩20,250-1,200-5.6%₩20,950₩21,050₩20,000228,450
₩21,450-350-1.6%₩21,650₩21,950₩20,950212,389
₩21,800-150-0.7%₩21,550₩22,500₩21,550193,982
₩21,950+300+1.4%₩22,100₩22,450₩21,700144,685
₩21,650-450-2.0%₩21,800₩22,750₩21,600206,186
₩22,100-150-0.7%₩22,150₩23,350₩21,700360,565
₩22,250+1,700+8.3%₩21,500₩22,950₩21,300295,200
₩20,550-1,250-5.7%₩22,050₩22,350₩19,850450,172
₩21,800-100-0.5%₩21,650₩22,600₩21,650194,529
₩21,900-100-0.5%₩21,150₩22,400₩20,650370,809
₩22,000-450-2.0%₩22,700₩23,100₩21,700230,587
₩22,450+400+1.8%₩22,050₩22,550₩21,400279,486
₩22,05000.0%₩21,850₩22,950₩21,750177,234
₩22,050+250+1.1%₩21,600₩22,300₩21,500129,265
₩21,800-400-1.8%₩21,600₩22,200₩21,550115,644
₩22,200+50+0.2%₩22,250₩22,400₩21,750162,343
₩22,150-150-0.7%₩22,300₩22,800₩21,950148,956
₩22,300+500+2.3%₩22,000₩22,900₩22,000184,115
₩21,800-1,350-5.8%₩23,000₩23,000₩21,450217,247
₩23,150-450-1.9%₩23,300₩23,600₩22,450145,720
₩23,600+750+3.3%₩22,750₩23,900₩22,200230,125
₩22,850-350-1.5%₩23,400₩23,950₩22,600151,122
₩23,200-650-2.7%₩23,650₩23,850₩22,900231,782
₩23,850+2,150+9.9%₩21,500₩23,850₩20,900270,491
₩21,700-450-2.0%₩21,800₩22,200₩20,250324,829
₩22,150-1,800-7.5%₩23,200₩23,600₩21,450332,076
₩23,950+550+2.4%₩23,250₩24,300₩23,050194,349
₩23,400-200-0.8%₩23,100₩23,500₩22,600172,429
₩23,600-950-3.9%₩24,550₩24,750₩23,550203,632
₩24,550-150-0.6%₩24,700₩24,900₩24,100185,294
₩24,700-50-0.2%₩24,850₩25,200₩24,500110,688
₩24,75000.0%₩24,650₩25,200₩24,650161,185
₩24,750-350-1.4%₩25,350₩25,800₩24,600191,512
₩25,100+950+3.9%₩24,050₩25,100₩23,850235,201
₩24,150-200-0.8%₩24,250₩24,650₩24,050141,960
₩24,350-1,050-4.1%₩24,800₩24,850₩23,850275,378
₩25,400+750+3.0%₩24,750₩25,800₩24,750271,616
₩24,650-250-1.0%₩24,800₩25,050₩24,500107,237
₩24,900-100-0.4%₩25,050₩25,250₩24,750115,822
₩25,000+450+1.8%₩24,450₩25,100₩24,200146,515
₩24,550-50-0.2%₩24,750₩24,900₩24,550125,250
₩24,600-300-1.2%₩24,950₩25,250₩24,60086,749
₩24,900+50+0.2%₩24,700₩24,950₩24,500111,119
₩24,850-500-2.0%₩25,100₩25,350₩24,250226,136
₩25,350+250+1.0%₩25,050₩25,500₩24,950178,199
₩25,100-400-1.6%₩24,900₩25,300₩24,850132,529
₩25,500+700+2.8%₩24,600₩25,500₩24,500275,355
₩24,800+200+0.8%₩24,300₩25,100₩24,300207,512
₩24,600-100-0.4%₩24,300₩25,450₩24,300195,576
₩24,700+750+3.1%₩24,050₩24,850₩23,900133,810
₩23,950+50+0.2%₩24,550₩24,800₩23,950165,655
₩23,900+250+1.1%₩24,000₩24,250₩23,250212,652
₩23,650-2,150-8.3%₩25,150₩25,250₩23,600323,893
₩25,800-200-0.8%₩25,400₩26,350₩25,150253,398
₩26,000+750+3.0%₩24,850₩26,250₩24,450322,329
₩25,250-900-3.4%₩26,500₩27,750₩24,700441,438
₩26,150+1,700+7.0%₩23,950₩28,000₩23,650621,692
₩24,450-400-1.6%₩24,650₩24,900₩22,550492,648
₩24,850+1,250+5.3%₩23,300₩24,950₩22,800336,625
₩23,600-150-0.6%₩23,550₩24,200₩23,000222,515
₩23,750+350+1.5%₩22,950₩24,050₩22,650349,400
₩23,400+850+3.8%₩23,350₩24,600₩23,200343,747

Splits

2 splits since 2008 · KRX:007390 · every price before a split is adjusted for it

DayRatioWhat
61-for-57Split
5-for-14Consolidation
Ticker
KRX:007390
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
KRX
Currency
KRW

NATURECELL Co., Ltd. on 6ix

Sector
Health care
Industry
Biotechnology

Valuation

EV/sales 51.4× against a median of 2.2×: the highest of 7 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
₩1.05T KRW
P/E
Loss
EV/sales
51.4×
EV/EBITDA
Negative EBITDA
Price/book
17.1×
Gross margin
49.3%
Operating margin
−17.9%
Net margin
−13.2%
Debt to equity
0.0×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
NATURECELL Co., Ltd. · KRX:007390US$803.4MUS$787.5Mn/a51.4×n/a17.1×−13.2%0.0×n/a
Pharming Group NV · EURONEXT:PHARMUS$840.1MUS$766.3M34.4×2.0×19.8×2.9×6.3%0.4×n/a
Corvus Pharmaceuticals, Inc. · NASDAQ:CRVSUS$815.7MUS$613.4Mn/an/an/a3.9×n/a0.0×1.64
Odyssey Therapeutics, Inc. · NASDAQ:ODTXUS$815.2MUS$512.7Mn/an/an/a2.2×n/a0.1×1.11
Arbutus Biopharma Corporation · NASDAQ:ABUSUS$796.4MUS$458.9M3.6×2.5×3.1×9.3×121.2%0.0×1.10
Genfleet Therapeutics (Shanghai), Inc. Class H · HKEX:2595US$787.5MUS$519.4Mn/a26.6×n/a3.3×n/a0.0×n/a
Shaanxi Micot Pharmaceutical Technology Co., Ltd. Class H · HKEX:2335US$778.7MUS$600.0Mn/an/an/a5.5×n/a0.0×n/a
Ironwood Pharmaceuticals, Inc. · NASDAQ:IRWDUS$778.1MUS$702.9M5.2×1.8×n/an/a37.4%n/a1.16
Syndax Pharmaceuticals, Inc. · NASDAQ:SNDXUS$772.7MUS$695.6Mn/a2.4×n/an/a−72.4%n/a0.64
MeiraGTx Holdings plc · NASDAQ:MGTXUS$766.4MUS$715.6M9.8×1.8×3.7×3.6×19.5%0.6×1.57
ORIC Pharmaceuticals, Inc. · NASDAQ:ORICUS$764.9MUS$503.6Mn/an/an/a2.3×n/a0.0×1.22
Median of the othersUS$783.1MUS$606.7M7.5×2.2×3.7×3.4×19.5%0.0×1.16

Team and board

DirectorRole
Jeong-Chan RaChairman

Events

QuarterResultsShare move
Q4 2024Mar 28, 2025 · After close+1.8%
Q3 2024Nov 9, 2024 · After close+4.3%
Q2 2024Aug 9, 2024 · After close−1.2%
Q1 2024May 14, 2024 · After close+1.3%
Q4 2023Mar 21, 2024 · After close+8.8%
Q3 2023Nov 14, 2023 · After close+0.7%
Q3 2021Nov 12, 2021+4.2%
Quarter to Jun 30, 2021Aug 17, 2021+2.1%
Quarter to Mar 31, 2021May 14, 2021+30.3%

Open Events

Financials

Annual, in KRW

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue20.7B32.3B19.4B21.3B22.2B16.7B23.1B26.7B27.2B26.8B
Cost of revenue11.3B15.4B11.2B12.2B12.8B9.12B10.2B15.7B19.6B22.9B
Gross profit9.46B16.9B8.19B9.10B9.37B7.60B12.9B11.0B7.62B3.93B
Research and development64.4M338.9M2.22B1.58B1.42B1.69B150.3M30.9M
Selling, general and administrative6.86B14.6B15.1B15.7B16.1B11.5B8.77B8.15B6.12B7.53B
Operating income-3.62B575.2M-10.7B-7.32B-14.3B-14.7B1.01B2.34B-1.20B-3.68B
Depreciation and amortization1.83B1.71B1.56B1.14B1.66B1.37B1.20B739.1M885.0M557.5M
EBITDA-1.79B2.28B-9.18B-6.18B-12.6B-13.3B2.21B3.08B-316.3M-3.12B
Interest expense200.5M168.0M1.15B1.72B750.7M488.5M0000
Income before tax-2.77B1.35B-11.6B-8.32B-32.0B-18.9B902.0M2.23B-460.7M-3.22B
Income tax00
Net income-2.84B1.23B-11.7B-6.81B-32.0B-18.9B902.0M2.23B-460.7M-3.22B
Earnings per share, basic-44.0519.05-182.06-108.78-511.45-308.3814.7439.36-8.15-59.29

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents16.8B857.0K29.9B31.3B32.6B41.5B21.2B38.0K9.04B3.29B
Short-term investments-320200-44007.00B25.0B300.0M10.0M
Receivables4.72B9.50B3.84B8.57B5.35B2.91B3.13B3.17B4.01B6.49B
Inventory5.89B2.97B3.21B3.05B3.15B3.15B3.14B3.20B4.72B5.66B
Current assets28.9B42.0B40.6B67.2B42.9B56.3B55.9B22.1B20.5B17.7B
Property, plant and equipment13.9B13.5B9.61B8.53B9.33B12.1B10.6B11.1B10.8B
Goodwill976.0M976.0M976.0M976.0M1.03B976.0M976.0M
Total assets74.7B72.0B68.4B94.0B69.6B85.7B93.1B52.9B51.4B52.7B
Accounts payable1.20B1.96B297.9M1.07B1.75B359.1M1.06B1.41B
Current liabilities8.70B4.12B4.21B35.8B6.58B20.5B8.84B9.28B9.66B11.5B
Long-term debt00023.0M69.0M1.87B6.24B
Total debt6.06B4.11B2.31B4.11B8.48B
Total liabilities11.7B7.37B6.98B36.9B8.80B23.1B11.2B9.75B12.0B18.6B
Shareholders' equity63.0B64.6B61.4B57.2B60.8B62.7B81.9B43.1B39.5B34.0B
Shares outstanding64.4M64.4M64.2M62.6M62.6M61.2M61.2M56.8M56.5M54.4M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations156.7M1.51B-2.13B-14.9B-10.1B-5.41B357.5M3.70B5.29B-2.14B
Capital spending-16.6B-3.12B-6.12B-3.80B-455.4M-2.72B-1.42B-413.7M-631.9M-2.00B
Free cash flow-16.4B-1.61B-8.25B-22.8B-9.89B-4.37B-1.24B3.29B4.66B-4.14B
Cash from investing-3.66B15.6B-15.3B4.82B15.5B-30.7B1.55B-1.06B-4.88B
Cash from financing190.1M-14.9B29.1B-3.71B10.3B36.6B398.3M1.57B4.79B
Share buybacks1.23B16.0B10.7M1.76B37.9B444.3M1.61B189.0M
Change in cash-11.6B-1.52B-1.36B-1.29B-8.95B20.3B6.36B5.82B5.60B-2.20B

Open Financials

Cap table

Built by 6ix from NATURECELL Co., Ltd.’s releases

Common shares
53,076,400
Fully diluted
53,076,400

Fully diluted

LineShares
Common shares53,076,400

Share count over time

CountShares
Nov 22, 202653,076,400

Open Cap table

Shareholders

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Jeong-Chan RaChairman · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about NATURECELL Co., Ltd.